Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegfilgrastim + plerixafor for stem cell mobilization in lymphoma and multiple myeloma
ACTRN12609000116224Phase 2Not yet recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Jun 2009
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegfilgrastim and plerixafor in lymphoma and multiple myeloma (MM), sponsored by Peter MacCallum Cancer Centre. Primary endpoints: Toxicity and adverse events and Peripheral blood CD34+ cell counts. Planned start Jun 2009; status: not yet recruiting.
02
Drugs
pegfilgrastimplerixafor
03
Conditions
lymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12609000116224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000116224.